A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Saved in:
| Title: | A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. |
|---|---|
| Authors: | Awada G; Departments of Medical Oncology., Schwarze JK; Departments of Medical Oncology., Tijtgat J; Departments of Medical Oncology., Fasolino G; Ophthalmology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels., Kruse V; Department of Medical Oncology, Universitair Ziekenhuis Gent, Ghent.; Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas (current affiliation).; Ghent University, Ghent (current affiliation).; University of Antwerp, Antwerp, Belgium (current affiliation)., Neyns B; Departments of Medical Oncology. |
| Source: | Melanoma research [Melanoma Res] 2022 Jun 01; Vol. 32 (3), pp. 183-191. Date of Electronic Publication: 2022 Mar 29. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35377866 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Awada+G%22">Awada G</searchLink>; Departments of Medical Oncology.<br /><searchLink fieldCode="AU" term="%22Schwarze+JK%22">Schwarze JK</searchLink>; Departments of Medical Oncology.<br /><searchLink fieldCode="AU" term="%22Tijtgat+J%22">Tijtgat J</searchLink>; Departments of Medical Oncology.<br /><searchLink fieldCode="AU" term="%22Fasolino+G%22">Fasolino G</searchLink>; Ophthalmology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels.<br /><searchLink fieldCode="AU" term="%22Kruse+V%22">Kruse V</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Gent, Ghent.; Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas (current affiliation).; Ghent University, Ghent (current affiliation).; University of Antwerp, Antwerp, Belgium (current affiliation).<br /><searchLink fieldCode="AU" term="%22Neyns+B%22">Neyns B</searchLink>; Departments of Medical Oncology. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229109623%22">Melanoma research</searchLink> [Melanoma Res] 2022 Jun 01; Vol. 32 (3), pp. 183-191. <i>Date of Electronic Publication: </i>2022 Mar 29. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9109623 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1473-5636 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209608931%22">09608931 </searchLink><i>NLM ISO Abbreviation: </i>Melanoma Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35377866 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1097/CMR.0000000000000821 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 183 Titles: – TitleFull: A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Awada G – PersonEntity: Name: NameFull: Schwarze JK – PersonEntity: Name: NameFull: Tijtgat J – PersonEntity: Name: NameFull: Fasolino G – PersonEntity: Name: NameFull: Kruse V – PersonEntity: Name: NameFull: Neyns B IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2022 Jun 01 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1473-5636 Numbering: – Type: volume Value: 32 – Type: issue Value: 3 Titles: – TitleFull: Melanoma research Type: main |
| ResultId | 1 |
